A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia

Gerald G. Wulf, Rui Yu Wang, Ingrid Kuehnle, Douglas Weidner, Frank Marini, Malcolm K. Brenner, Michael Andreeff, Margaret A. Goodell

Research output: Contribution to journalArticle

282 Scopus citations

Abstract

The hematopoietic stem cell underlying acute myeloid leukemia (AML) is controversial. Flow cytometry and the DNA-binding dye Hoechst 33342 were previously used to identify a distinct subset of murine hematopoietic stem cells, termed the side population (SP), which rapidly expels Hoechst dye and can reconstitute the bone marrow of lethally irradiated mice. Here, the prevalence and pathogenic role of SP cells in human AML were investigated. Such cells were found in the bone marrow of more than 80% of 61 patients and had a predominant CD34low/-immunophenotype. Importantly, they carried cytogenetic markers of AML in all 11 cases of active disease examined and in 2 out of 5 cases in complete hematological remission. Comparison of daunorubicin and mitoxantrone fluorescence emission profiles revealed significantly higher drug efflux from leukemic SP cells than from non-SP cells. Three of 28 SP cell transplants generated overt AML-like disease in nonobese diabetic-severe combined immunodeficient mice. Low but persistent numbers of leukemic SP cells were detected by molecular and immunological assays in half of the remaining mice. Taken together, these findings indicate that SP cells are frequently involved in human AML and may be a target for leukemic transformation. They also suggest a mechanism by which SP cells could escape the effects of cytostatic drugs and might eventually contribute to leukemia relapse.

Original languageEnglish (US)
Pages (from-to)1166-1173
Number of pages8
JournalBlood
Volume98
Issue number4
DOIs
StatePublished - Aug 15 2001

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this